COMPLETED: Consortium on Targeting and Regeneration (HIRN-CTAR)
CTAR is investigating methods to increase or maintain functional beta cell mass in T1D through targeted manipulation of islet plasticity or engineered protection of beta cells from immune-mediated destruction. Active: September 2014 – November 2023 |